Rapport Therapeutics, Inc. Payments to Acquire Investments
Rapport Therapeutics, Inc. (RAPP) reported Payments to Acquire Investments of $70.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- Rapport Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $39.67M, a 208.55% increase year-over-year.
- Rapport Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $30.37M, a 29.76% decline year-over-year.
- Rapport Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $197.07M, a 133.06% increase year-over-year.
- Rapport Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $101.62M, a 7.40% decline year-over-year.
- Rapport Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $354.78M, a 6.03% decline from fiscal 2024.
- Rapport Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $377.53M, a 388.88% increase from fiscal 2023.
- Rapport Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $77.22M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $70.04M 10-Q · filed 2026-08-05 | $267.12M derived: sum of 3 quarters · filed 2026-08-05 | $368.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $30.37M 10-Q · filed 2026-05-07 | $227.44M derived: sum of 2 quarters · filed 2026-05-07 | $329.06M derived: sum of 3 quarters · filed 2026-05-07 | $341.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $197.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $298.69M derived: sum of 2 quarters · filed 2026-03-10 | $311.55M derived: sum of 3 quarters · filed 2026-08-05 | $354.78M 10-K · filed 2026-03-10 |
| 2025-09-30 | $101.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $114.48M derived: sum of 2 quarters · filed 2026-08-05 | $157.71M 10-Q · filed 2025-11-06 | $242.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $12.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $56.09M 10-Q · filed 2026-08-05 | $140.65M derived: sum of 3 quarters · filed 2026-08-05 | $250.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $43.23M 10-Q · filed 2026-05-07 | $127.79M derived: sum of 2 quarters · filed 2026-05-07 | $237.54M derived: sum of 3 quarters · filed 2026-05-07 | $375.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $84.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $194.30M derived: sum of 2 quarters · filed 2026-03-10 | $332.73M derived: sum of 3 quarters · filed 2026-03-10 | $377.53M 10-K · filed 2026-03-10 |
| 2024-09-30 | $109.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $248.17M derived: sum of 2 quarters · filed 2025-11-06 | $292.97M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $138.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $183.23M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $44.80M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $77.22M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |